SCHEDULE: Invus Entities Disclose 6.1% Stake in Tango Therapeutics
Beneficial Ownership Report
Invus Public Equities, Avicenna Life Sci Master Fund, and related entities, including Raymond Debbane, reported beneficial ownership of 6.1% of Tango Therapeutics, Inc. common stock as of December 31, 2025.
Summary
- Invus Public Equities, L.P. and Avicenna Life Sci Master Fund LP, along with their controlling entities and Raymond Debbane, collectively reported beneficial ownership of Tango Therapeutics, Inc. common stock.
- Raymond Debbane is deemed to beneficially own 8,165,374 shares, representing 6.1% of the company's outstanding common stock.
- Invus Public Equities, L.P. directly holds 7,068,444 shares, equating to 5.3% of the class.
- Avicenna Life Sci Master Fund LP directly holds 1,096,930 shares, representing 0.8% of the class.
- The beneficial ownership percentages are calculated based on 134,593,998 shares outstanding as of October 28, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 4, 2025.
- The reporting persons certified that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, except for activities related to a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as Schedule 13G reports are routine disclosures of beneficial ownership and do not inherently convey positive or negative sentiment regarding the company's performance or prospects.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are standard disclosures for institutional investors who acquire more than 5% of a company's voting securities, indicating a passive investment intent. This filing reveals a significant stake by Invus-related entities in Tango Therapeutics, a biotechnology company, which is common for specialized funds focusing on life sciences.
Related Party Transactions
- Invus Public Equities, L.P. is controlled by Invus Public Equities Advisors, LLC, which is controlled by Invus Global Management, LLC, which is controlled by Siren, L.L.C.
- Avicenna Life Sci Master Fund LP is controlled by Avicenna Life Sci Master GP LLC, which is controlled by Ulys, L.L.C.
- Raymond Debbane is the managing member of both Siren, L.L.C. and Ulys, L.L.C., thereby controlling all the aforementioned entities and their beneficial ownership. This establishes a clear chain of control and relatedness among the reporting persons.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, potentially signaling confidence from a large investor.
- Management: Awareness of a significant passive shareholder group, though the filing certifies no intent to influence control.
Key Dates
| Date | Description |
|---|---|
| 2025-10-28 | Date shares outstanding were reported in Issuer's 10-Q. |
| 2025-12-31 | Date of event which requires filing of this statement (beneficial ownership snapshot date). |
| 2026-02-13 | Filing date of the Schedule 13G Amendment No. 1. |
Keywords
Tango Therapeutics, Invus Public Equities, Avicenna Life Sci Master Fund, Raymond Debbane, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.